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Abstract. 28 
Two separate species of Ureaplasma have been identified that infect humans: Ureaplasma 29 
parvum and Ureaplasma urealyticum.  Most notably, these bacteria lack a cell wall and are 30 
the leading infectious organism associated with infection-related induction of preterm birth.  31 
Fourteen separate representative prototype bacterial strains, called serovars, are largely 32 
differentiated by the sequence of repeating units in the C-terminus of the major surface 33 
protein: multiple-banded antigen (MBA).  Monoclonal antibodies that recognise single or 34 
small groups of serovars have been previously reported, but these reagents remain sequestered 35 
in individual research laboratories.  Here we characterise a panel of commercially available 36 
monoclonal antibodies raised against the MBA and describe the first monoclonal antibody 37 
that cross-reacts by immunoblot with all serovars of U. parvum and U. urealyticum species.  38 
We also describe a recombinant MBA expressed by E. coli which facilitated further 39 
characterisation by immunoblot and demonstrate immunohistochemistry of paraffin-40 
embedded antigens.  Immunoblot reactivity was validated against well characterised 41 
previously published monoclonal antibodies and individual commercial antibodies were found 42 
to recognise all U. parvum strains, only serovars 3 and 14 or only serovars 1 and 6, or all 43 
strains belonging to U. parvum and U. urealyticum.  MBA mass was highly variable between 44 
strains, consistent with variation in the number of C-terminal repeats between strains.  45 
Antibody characterisation will enable future investigations to correlate severity of 46 
pathogenicity to MBA isoform number or mass, in addition to development of antibody-based 47 
diagnostics that will detect infection by all Ureaplasma species or alternately be able to 48 
differentiate between U.parvum, U.urealyticum or mixed infections. 49 
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1. INTRODUCTION 51 
Ureaplasma species are one of the smallest, free living mucosal bacteria that can be isolated 52 
from the human urogenital tract.  These organisms are the most common bacteria isolated 53 
from infected amniotic fluid and placentas, and they contribute to adverse pregnancy 54 
outcomes including preterm birth and neonatal morbidities. In a recent review, the rate of 55 
Ureaplasma infection was reported to be almost half of the preterm infants of less than 32 56 
weeks gestation in one or more compartment (respiratory, blood and/or cerebrospinal fluid), 57 
indicating that these organisms were the most common pathogens affecting this population 58 
[1]. Furthermore, intrauterine or perinatal infection with Ureaplasma species is emerging as a 59 
leading risk factor for adverse pregnancy outcomes and complications of extreme preterm 60 
birth such as bronchopulmonary dysplasia BPD and intraventricular haemorrhage [2]  Recent 61 
meta-analysis of 39 studies examining the role of Ureaplasma and development of BPD 62 
supported a significant association between pulmonary colonization with Ureaplasma and 63 
development of BPD in preterm infants [3]. 64 
However, Ureaplasma were initially described in isolates from male patients suffering from 65 
urethritis.  The initial 1954 report [4] differentiated Ureaplasma from Mycoplasma based on 66 
agar plate colony morphology (initially designated T-mycoplasma for “tiny” colony, which 67 
were visually distinct from the larger characteristic Mycoplasma “fried egg” morphology).  68 
By 1982, Robertson and Stemke [5] had separated Ureaplasma into 14 “serovars” using a 69 
panel of polyclonal rabbit anti-sera and a combination of modified metabolic inhibition test 70 
and colony indirect epifluorescence methods.  In the years that followed, it became clear that 71 
these 14 serovars could be grouped into two separate sub-types that were initially called 72 
“biovar” 1 and 2.  However, in 2002 Robertson et al., utilised conserved differences in DNA-73 
DNA hybridisation, distinctive RFLP patterns, and other genomic differentiators to divide the 74 
14 serovars into two distinct species: U. parvum (serovars 1, 3, 6 and 14) and U. urealyticum 75 
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(serovars 2, 4, 5, and 7-13) [6]. A conserved PCR amplicon size difference using primers 76 
recognising the promoter and coding region of the major surface protein (multiple banded 77 
antigen; MBA) was found capable of separating clinical U. parvum (403 bp) from U. 78 
urealyticum (448 bp) strains [7].  These authors also found that different sized amplicons for 79 
related primer sets in this region could also separate U. urealyticum serovars 2, 5, 7, 8, 9 and 80 
11 from U. urealyticum strains 4, 10, 12 and 13, as well as uniquely identifying U. parvum 81 
serovar 6 from all other isolates [7].  The MBA is a lipid-anchored protein that is expressed 82 
on the surface of Ureaplasma and is composed of a signal peptide, a lipid anchor addition 83 
signal sequence and a relatively well conserved non-repeating region of approximately 100 84 
residues at the N-terminus.  However, the C-terminus region is composed of repeats that vary 85 
in sequence between serovars and in repeat number amongst strains of the same serovar.  86 
Kong et al., [8] found that the predicted amino acid sequence for the repeat region of each U. 87 
parvum serovar (1, 3, 6 and 14) was slightly different and that U. urealyticum serovars could 88 
be separated into a unique serovar 10 repeat (genotype B, repeat TQPGSGST) and two groups 89 
(with identical MBA N-terminal repeats) encompassing serovars 2, 5 and 8 (genotype A; 90 
repeat TKPGSGET) and serovars 4, 12 and 13 (genotype C; repeat TSPEKPGNGT), but that 91 
serovars 7, 11 (genotype E) and 9 (genotype D) could not be differentiated by consensus 92 
MBA repeat sequence in their study.  These defined consensus external repeats make ideal 93 
targets for differentiation by antibodies and development of monoclonal antibodies against the 94 
MBA have also been reported [9-13].  Some monoclonal antibodies recognise single serovars, 95 
while others recognise groups of U. parvum or U. urealyticum sub-groups.  However, all of 96 
these antibodies belong to independent research groups and are not readily available.  Here we 97 
provide the first characterisation of commercially available monoclonal antibodies by 98 
immunoblot against the initial prototype serovar strains and validate our results against a 99 
panel of research monoclonal antibodies that have previously been published.  100 
101 
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2. MATERIALS AND METHODS 102 
2.1 Antibodies 103 
 A panel of mouse monoclonal antibodies previously characterised and published [9, 104 
10] (provided by Dr. Gail Cassell) were used for comparison.  These antibodies included 105 
clones 8A1.2 (specific for serovar 10), 10C6.6 (specific for serovar 3), 5B1.1 (specific for 106 
serovars 3 and 14 only) and 8B5.2 (specific for serovars 1, 3, 6 and 14; all U. parvum strains).  107 
Commercial monoclonal antibodies were provided by ViroStat Inc. (Portland, ME) and 108 
included catalogue numbers 6522, 6523, 6525, 6527 as well as clones 4H2 and 2G9.  Isotype 109 
control (IgG1) monoclonal antibody was purchased from Caltag MedSystems ltd 110 
(Buckingham, UK).  Peroxidase-conjugated donkey anti-mouse immunoglobulin secondary 111 
antibodies were purchased from Jackson ImmunoResearch Europe ltd. (Newmarket, Suffolk, 112 
UK).  113 
2.2 Bacterial strains 114 
 Prototype strains representing serovars 1-14 were obtained from the American type 115 
culture collection (strains 27813 (SV1); 28715 (SV3); 27818 (SV6); 33967 (SV14); 27814 116 
(SV2); 27816 (SV4); 27817 (SV5); 27819 (SV7); 27618 (SV8); 33175 (SV9); 33699 (SV10); 117 
33695 (SV11); 33696 (SV12) and 33698 (SV13)).  Ureaplasma strains were cultured in 118 
Ureaplasma selective medium (Mycoplasma Experience ltd; Reigate, Surrey, UK) as 119 
previously published.  Clinical isolates of U. urealyticum originated from a previously 120 
published study examining antibiotic susceptibility for clinical isolates in England and Wales 121 
between 2003-2009 [14], as were U. parvum strains HPA2 (SV6), HPA5 (SV3) and HPA32 122 
(SV14) which have been further characterised in other investigations [15, 16].   123 
2.3 Creation of E. coli expressing recombinant serovar 3 MBA. 124 
 A codon optimised gene for expressing the serovar 3 MBA protein (only encoding 2 125 
PAGKEQ C-terminal repeats) was created by utilising the Life Technologies online tool to 126 
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generate the DNA sequence optimised for E. coli expression following input of the following 127 
amino acid sequence (supplementary figures 1 and 2).  The promoter for the tuf gene from 128 
serovar 3 (170 bp upstream of the AUG start codon) was then added upstream of this 129 
optimised open-reading frame to promote expression.  This sequence was synthesized by 130 
MWG Eurofins (Ebersberg, Germany) which was provided in the ampicillin resistant plasmid 131 
pEX-A2.  A HinDIII restriction site was engineered into the sequence just prior to the 132 
PAGKEQ repeats so that digestion with HinDIII and re-ligation would result in expression of 133 
serovar 3 MBA that ended in FETTQPGKL rather than FETTQPGKLPAGKEQPAGKEQ.  134 
One shot Top10 chemically competent E. coli (Invitrogen; Paisley, Scotland, UK) were 135 
transformed with full or HinDIII truncated plasmids, as per manufacturer’s instructions.  This 136 
bacteria has the genotype F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 137 
araD139 Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG λ-.  Single colonies of 138 
transformed bacteria were picked from LB agar plates containing 100 mg/L ampicillin and 139 
grown up in LB broth containing ampicillin for further analysis.  Control bacteria containing 140 
empty EX-A2 plasmid were used as controls. 141 
 142 
2.4 Immunoblot analysis 143 
 Ureaplasma strains to be analysed for Immunoblot analysis were grown up in 5 ml of 144 
Ureaplasma selective medium for 48 h and pelleted at 17,000 xg for 30 min, prior to being 145 
washed by resuspension in PBS and re-pelleted (repeated 3 times).  Bacterial pellets were 146 
solubilised in 1% SDS (25 µL) before addition of an equal volume of LDS-sample buffer 147 
(Invitrogen) and boiled at 95oC for 5 min prior to loading on a non-reducing SDS 148 
polyacrylamide gel (7.5% polyacrylamide) and separated by electrophoresis.  MagicMarkTM 149 
molecular mass protein standards were run on each gel to determine relative molecular mass 150 
of proteins.  Proteins were transferred electrophoretically to 0.22 µm nitrocellulose membrane 151 
  Aboklaish/Ahmed et al. 
7 
 
and blocked for 1 h in PBS containing 0.05% Tween20 (PBST) and 10% lyophilised skim 152 
milk.  Monoclonal antibodies were added to a final concentration of 10 µg/ml and incubated 153 
on a roller overnight at 4oC.  Unbound monoclonal antibodies were removed by 3 washes in 154 
PBST prior to detection with secondary antibody for 1 h at room temperature.  Peroxidase 155 
secondary antibodies were detected by ECL Western blotting substrate (Pierce ltd.) and 156 
exposure to X-ray film (FujiFilm).  Sequencing of the mba gene in clinical samples to 157 
determine the serovar of clinical U. urealyticum isolates was performed by amplifying the 158 
mba gene by PCR using the primers revMBA Uu2 (GTTTTGTAGTTTCACCACTTCC) and 159 
UMS-125 [7] and sending the purified amplicon to MWG Eurofins for sequencing.  Expasy 160 
translate tool (http://web.expasy.org/translate/) was used to determine the amino acid 161 
sequence of the mba gene for manual identification of repeating sequences. 162 
 Recombinant proteins expressed in E.coli were performed on a 1 ml culture grown in 163 
LB broth containing ampicillin and pellets were solubilised in 1% SDS prior to addition of an 164 
equal volume of LDS sample buffer (Invitrogen) and analysed by immunoblot analysis as 165 
above. 166 
2.5 Immunohistochemistry analysis 167 
 Pellets generated from a 10 ml HPA5 (SV3) culture, centrifuged at 17,000 xg, or 168 
single colonies of E.coli (transformed with either the recombinant MBA expression cassette 169 
or empty control vector) cut from the surface of LB agar plates, were embedded in paraffin 170 
using an automated processor.  Sections (5 µm thick) were cut and mounted on glass slides, 171 
prior to rehydration and antigen retrieval for 10mM citrate containing 0.005% Tween 80 at 172 
95oC for 1 hour.  Sections were then stained with 10 µg/mL primary antibody (6522, 6523, 173 
6525 or isotype control) diluted in 10mM PBS containing 0.6% BSA (PBS/BSA).  Following 174 
removal of unbound antibody by washing in PBS/BSA, sections were incubated with 1/100 175 
dilution of peroxidase-conjugated donkey anti-mouse immunoglobulin secondary antibody for 176 
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1 hour.  Following further washing steps peroxidase was developed for 3 minutes in 0.025% 177 
diaminobenzamidine containing H2O2. Where indicated sections were also counterstained for 178 
10 sec in 0.02% picromethyl blue prior to dehydration, clearing in xylene and mounting under 179 
a coverslip. 180 
 181 
RESULTS 182 
Screening prototype Ureaplasma parvum strains with monoclonal antibodies.  183 
Equal amounts of serovars 1, 3, 6 and 14 were separated by SDS-PAGE and transferred 184 
to nitrocellulose prior to probing with monoclonal antibodies (Figure 1).  Monoclonal 185 
antibodies 6522, 6523 and 6527 each recognised all four serotypes of U. parvum (Figure 1A).  186 
Whereas antibody 6525 only recognised serovars 3 and 14 and antibodies 4H2 and 2G9 only 187 
recognised serovars 1 and 6.  These results were validated against the pattern of MBA detection 188 
by monoclonal antibodies previously published by Watson et al. [9] (Figure 1B).  Monoclonal 189 
antibody clone 10C6.6 (previously reported only to detect serovar 3 MBA) bound to a single 190 
band of 50 kDa mass from serovar 3 (Figure 1B), while clone 5B1.1 (previously reported to 191 
only detect serovar 3 and 14) bound to this band and an additional single band of mass 150 kDa 192 
for serovar 14 (Figure 1B).  Monoclonal antibody clone 8B5.2 (previously reported to only 193 
detect MBA from all U. parvum serovars) detected these two bands in addition to a 72 kDa 194 
band for serovar 1 and a 70 kDa band for serovar 6 (Figure 1B).  As expected clone 8A1.2 195 
(specific for U. urealyticum serovar 10) did not recognise any of these strains.  Of importance, 196 
the visualised relative molecular mass for each prototype strain was the same for each antibody.   197 
Screening prototype Ureaplasma urealyticum strains with monoclonal antibodies.  198 
Next all antibodies were tested against the full panel of U. urealyticum prototype strains 199 
(with U. parvum strains included for reference).  No additional reactivity beyond that shown in 200 
Figure 1 was observed for monoclonal antibodies 6525, 6527, 4H2, 2G9, 10C6.6, 8B5.2, or 201 
  Aboklaish/Ahmed et al. 
9 
 
5B1.1 (data not shown).  However, antibody 6523 also reacted (to a lesser intensity) with single 202 
bands of 60 and 70 kDa for serovars 7 and 11 respectively (Figure 2), whereas antibody 6522 203 
recognised single bands for all strains of both U. parvum and U. urealyticum (Figure 2).  204 
Repeated investigation of 6522 against all the prototype U. urealyticum strains as well as 11 205 
additional untyped clinical U. urealyticum strains (Figure 3) gave the same results for the 206 
prototype strains.  Most of the clinical strains gave a single band and the relative mass of these 207 
bands varied from strain to strain.  To validate these findings duplicate blots were probed with 208 
previously characterised clone 8A1.2 [9] which is specific for serovar 10.  This antibody 209 
recognised the same band in the prototype serovar 10 strain and bands for each of the clinical 210 
strains HPA24 and 31 as identified by serovar 10 specific clone 8A1.2.  Sequencing the 211 
variable region of the mba genes from HPA 24 and 31 confirmed they were only isolate in the 212 
untyped clinical collection to have the repeating TQPGSGST amino acid sequence in the C-213 
terminus of the gene also found in our prototype serovar 10 strain (data not shown).   214 
Immunoblot analysis of recombinant serovar 3 MBA expressed by E.coli.  215 
All monoclonal antibodies were then used to analyse immunoblots containing E.coli 216 
transformed with plasmids containing a codon optimised gene serovar 3 mba gene encoding 217 
two PAGKEQ repeats, a truncated gene with these repeats removed, or E.coli transformed with 218 
the empty vector (Figure 4).  As expected, monoclonal antibodies that only recognise serovar 219 
10 (clone 8A1.2) or serovars 1 and 6 (4H2 and 2G9) failed to react with these recombinant 220 
MBA proteins.  Monoclonal antibodies 10C6.6 and 5B1.1 only reacted with MBA proteins that 221 
contained the PAGKEQ repeat, indicating the recognition epitope is located in the C-terminal 222 
repeat region.  The remaining antibodies recognised the recombinant MBA with and without 223 
the C-terminal repeats equally, indicating that the epitope they recognise is a conserved 224 
sequence in the non-repeating N-terminal sequence. 225 
 226 
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Use of monoclonal antibodies to detect MBA in paraffin-embedded sections.  227 
Next we endeavoured to see if the commercial monoclonal antibodies could detect MBA 228 
antigen by immunohistochemistry in paraffin sections.  Initially we examined pelleted broth 229 
cultures of serovar 3 (Supplementary figure 3), which showed clear specific reactivity with 230 
antibodies 6522, 6523 and 6525 relative to matched isotype controls; however, morphology of 231 
centrifuged pellets were amorphous.  Therefore, to prove specificity and gain a better target for 232 
staining, single colonies of E.coli expressing the recombinant form of serovar 3 MBA utilised 233 
for immunohistochemistry analysis.  These paraffin-embedded colonies showed clear outlines 234 
of individual bacillus that were not apparent when monoclonal antibodies were used to stain 235 
control E. coli colonies transformed with empty vector (Figure 5).  Successful staining with 236 
monoclonal antibodies was only seen following antigen retrieval processing (1 h treatment with 237 
citrate buffer at 95oC). 238 
  239 
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DISCUSSION 240 
Ureaplasma is one of the smallest self-replicating organisms with a minimal genome, ranging 241 
in size from 0.75 to 0.95 Mbp [17].  These genomes are predicted to encode on average 604 (U. 242 
parvum) or 664 (U. urealyticum) protein encoding genes, with 515 genes universally conserved 243 
across all serovars.  There are several distinct phylogenetic markers that separate the U. parvum 244 
and U. urealyticum species [6] and these species are readily distinguished by standard PCR 245 
using primers that amplify a region from 125 bp upstream of the AUG start codon and 226 bp 246 
at the 5’ end of the gene [7].  The MBA protein is an excellent target for separation of the 247 
Ureaplasmas into distinct sub-groups as it is highly expressed, often being a prominent band of 248 
unique mass between strains when separated by SDS-PAGE and stained with Coomassie blue.  249 
It is likely to represent a significant immunological target and the predicted amino acid 250 
sequence readily separates the U. parvum serovars: PGKEQQ (SV1), PAGKEQ (SV3), PGKE 251 
(SV6), and PAGKEQQ (SV14).  However, all serovars cannot be completely resolved from 252 
one another based on MBA sequence (e.g. serovars 2, 5 and 8 all have the TKPGSGET repeat).  253 
Molecular methods of separating the serovars based on targets external to the mba gene were 254 
reported to successfully separate the prototype strains [18]; unfortunately application of these 255 
typing schemes to clinical isolates did not maintain clear serovar differentiation [19], likely due 256 
to a propensity for Ureaplasma species to undergo extensive horizontal gene transfer [17]. 257 
There have been several reports for the development of monoclonal antibodies that recognise 258 
serovars in the past.  The first report was by Watson et al. [9] where a panel of monoclonal 259 
antibodies were characterised and antibodies that recognised individual serovars 3, 8 and 10 260 
were identified, and two of these antibodies have served as reference for the characterisation we 261 
present here.  Some of these original reference antibodies had been further characterised by 262 
peptide mapping to identify the key aspects of the epitopes recognised.  Amino acid sequences 263 
of the repeat region identified motifs that differentiated serovar 3 specific mAbs 10C6.6 264 
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(KEQPA) and 3B1.5 (EQP) from an antibody (5B1.1) that recognised both serovars 3 and 14 265 
equally (GK) [10].  Our results confirm that the epitopes for 10C6.6 and 5B1.1 are definitively 266 
found in the repeat sequence (Figure 4); however 5B1.1 did not recognise our truncated 267 
recombinant MBA which ends in PGKL, suggesting that the GK alone cannot bind the 268 
antibody and significant influence is played by the preceding A or adjacent E in the conserved 269 
repeat sequence unique for serovars 3 and 14.  Other mAbs that have been characterised bind 270 
specifically to serovar 4 [11], serovar 9 [13], and serovar 1, 3, or 6 [12].  However, the one 271 
commonality of these previously characterised reagents is their sequestration in individual 272 
research laboratories.  Here we have characterised a panel of commercially available 273 
monoclonal antibodies and found the first monoclonal antibody (6522) that can recognise all 274 
strains of U. parvum and U. urealyticum.  We also found an antibody that only recognises 275 
epitopes common to U. parvum (6527) as well as one that recognises all U. parvum and weakly 276 
binds to serovars 7 and 11 (which together form the unique MBA genotype E as previously 277 
reported by Kong et al. [8]).  Comparison of the N-terminus of all MBA sequences for 278 
Ureaplasma parvum and urealyticum strains show several conserved homologous regions 279 
containing hydrophilic and charged residues for both species or conserved only within U. 280 
parvum (data not shown); however, exactly where monoclonal antibodies 6522, 6523 and 6527 281 
bind would require an extensive mapping investigation using truncated recombinant genes or a 282 
panel of peptides.  The weak recognition of serovars 7 and 11 in addition to U. parvum by 6523 283 
is difficult to explain as there is no obvious region that separates these two serovars from the 284 
remaining U. urealyticum strains.  With regards to previously published monoclonal antibodies, 285 
comparison of the amino acid sequence of the repeat regions shows differences that justify how 286 
antibodies could specifically recognise serovars 1, 3, 6, 9, and 10 uniquely, but the shared 287 
MBA sequence of serovar 4, 10, 12 and 13 and 2, 5 and 8 make it difficult to accept antibodies 288 
that uniquely detect the MBA for serovar 4 [11] and serovar 8 [9].  However, development of 289 
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monoclonal antibodies that specifically recognise proteins unique to serovars 2, 5, 7, 8 10, 11, 290 
12 and 13, that are not raised against the MBA, have been reported [20] We have validated the 291 
bands recognised by the commercial antibodies against previously characterised antibodies, to 292 
confirm it is the MBA protein that the commercial antibodies are binding. 293 
Using the MBA as a method to classify strains is not without potential disadvantages.  The 294 
MBA is phase variable.  When grown in the presence of rabbit polyclonal anti-MBA 295 
antibodies, expression has been found to be shut off [21], as have selection of non-adherent 296 
sub-populations [22].  The mechanism of phase variation is speculated to involve tyrosine 297 
recombinases (particularly XerC) and inversion of promoter regions driving expression of the 298 
open-reading frames [23, 24].  The propensity for recombination can also result in multiple 299 
copies of the mba gene being present in the genome and comparative genomic analysis has 300 
suggested that repeats characteristic of different serovars can be found in a single genome of 301 
the same strain [17]; however, no evidence of co-expression of separate serovar repeat 302 
expression was provided in that report, and we have not found co-expression of different MBA 303 
in our investigations.  In our laboratory, for all cases where isolates were found to express more 304 
than one MBA, we were able to purify these to single isoform expression by picking single 305 
colonies from plates (data not shown); however, this does not imply that expression of two or 306 
more MBA is not possible in clinical isolates. 307 
The original serotyping methods utilised a modified metabolism inhibition assay where the 308 
typing polyclonal anti-serovar sera were found to alter metabolism of matching strains through 309 
an unknown mechanism.  Watson et al. [9], confirmed that 4 of 6 monoclonal antibodies also 310 
had differing capacities to inhibit metabolism of matching serovars.  Whether different epitopes 311 
on the MBA relate to metabolic inhibition, or whether only those monoclonal antibodies that 312 
recognise epitopes available in the native protein inhibited metabolism remains unknown.  313 
While it is difficult to speculate a mechanism for how antibody binding to a lipid anchored 314 
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bacterial protein would result in bactericidal or bacteriostatic activity, the future of anti-MBA 315 
monoclonal antibodies as therapeutics to exploit this phenomenon remains open. 316 
Here we provide a detailed analysis that differentiates between the reactivity of a panel of 317 
monoclonal antibodies raised against the MBA.  The results will enable other researchers to 318 
speciate clinical isolates, or assign specific serovars in some cases, based on differential 319 
detection by immunoblot or immunohistochemistry.  More importantly, these reagents will 320 
enable researchers to begin to examine correlations between MBA size or mixed MBA 321 
isoforms present in each sample, rather than just nucleic acid determinations.  This may be of 322 
particular importance for future investigations as experimental investigations in pregnant sheep 323 
have found increased pathology when less than 5 MBA isoforms were observed compared to 324 
pregnant sheep infected with 9 or more MBA isoforms for the same strain [25]. 325 
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Figure Legends 333 
Figure 1. Immunoblot analysis of whole bacterial proteins from prototype U. parvum 334 
serovars.  A. MBA proteins detected by commercial anti-MBA monoclonal antibodies 335 
separated on by non-reducing SDS-PAGE. B. Validation of bands detected by commercial 336 
antibodies by comparison to previously characterised antibodies from Watson et al. [9] known 337 
to bind serovar 3 only (10C6.6), serovar 3 and 14 only (5B1.1) and all U. parvum MBA 338 
(8B5.2).  No signal was detected for serovar 10 specific clone 8A1.2.  Representative blots 339 
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shown for multiple repeats.  Molecular mass for each serovar was maintained for each 340 
detected MBA, validating the reactivity of the monoclonal antibodies. 341 
Figure 2. Immunoblot analysis of whole bacterial proteins from prototype U. parvum and U. 342 
urealyticum strains separated by non-reducing SDS-PAGE and transferred to nitrocellulose 343 
prior to probing with commercial antibodies 6522 and 6523. Relative molecular mass of MBA 344 
bands for specific serovar 1, 3, 6, 7, 11 and 14 strains where identical when detected by either 345 
antibody.  Representative blot from multiple repeats of the experiment are shown. 346 
Figure 3. Immunoblot analysis of whole bacterial proteins from prototype U. urealyticum 347 
strains (A) and 11 clinical isolates (B) by 6522 following separation by non-reducing SDS-348 
PAGE and transfer to nitrocellulose. An identical blot was probed in parallel with the serovar 349 
10 specific clone 8A1.2.  Comparison of the detected MBA species shows bands of exactly the 350 
same relative mass were detected for both antibodies, with the exception that 8A1.2 only 351 
detected the higher band for serovar 10 (C) and HPA24 (D).  Sequencing of N-terminus of 352 
clinical isolates HPA24 and 31 confirmed they were the only strains with the unique 353 
TQPGSGST repeat found to be unique to serovar 10 MBA. 354 
Figure 4. Immunoblot analysis of whole bacterial proteins from E.coli transformed with 355 
plasmids containing the mba gene containing two PAGKEQ repeats (R) or truncated to 356 
remove the repeats (T) as well as bacteria transformed with an empty vector (C).A. MBA 357 
proteins detected by commercial anti-MBA monoclonal antibodies separated on by non-358 
reducing SDS-PAGE. B. Validation of bands detected by commercial antibodies by 359 
comparison to previously characterised antibodies from Watson et al. [9].  Representative 360 
blots shown for multiple repeats.   361 
Figure 5. Immunohistochemistry visualisation of synthetic serovar 3 MBA expressed by 362 
transformed E.coli by monoclonal anti-MBA 6522 (B) 6523 (C) and 6525 (D) as compared to 363 
6522 staining of E.coli that are transformed with an empty plasmid (A).  Counterstaining 364 
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E.coli bacilli with Gram-stain obscures the peroxidase staining (inset C), therefore, no counter 365 
stain was used in the larger images, although outline of individual bacilli at the edge of 366 
colonies are distinguishable in B-D.  Images are taken with oil-emersion 100x objective lens, 367 
scale bar included to indicate magnification. 368 
 369 
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Figure 4. Immunoblot analysis of whole bacterial proteins from E.coli transformed with 1 
plasmids containing the mba gene containing two PAGKEQ repeats (R) or truncated to 2 
remove the repeats (T) as well as bacteria transformed with an empty vector (C).A. MBA 3 
proteins detected by commercial anti-MBA monoclonal antibodies separated on by non-4 
reducing SDS-PAGE. B. Validation of bands detected by commercial antibodies by 5 
comparison to previously characterised antibodies from Watson et al. [9].  Representative 6 
blots shown for multiple repeats.   7 
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Figure 5. Immunohistochemistry visualisation of synthetic serovar 3 MBA expressed by 
transformed E.coli by monoclonal anti-MBA 6522 (B) 6523 (C) and 6525 (D) as compared to 
6522 staining of E.coli that are transformed with an empty plasmid (A).  Counterstaining 
E.coli bacilli with Gram-stain obscures the peroxidase staining (inset C), therefore, no counter 
stain was used in the larger images, although outline of individual bacilli at the edge of 
colonies are distinguishable in B-D.  Images are taken with oil-emersion 100x objective lens, 
scale bar included to indicate magnification. 
